Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789570 | 0.92 | SLC6A2 (0.46) | CYP3A4TSHRALDH1A1MAPK1SLC6A2 | |
| SCHEMBL3781164 | 0.92 | SLC6A2 (0.50) | CYP3A4TSHRALDH1A1MAPK1SLC6A2 | |
| SCHEMBL3786337 | 0.90 | SLC6A2 (0.49) | CYP3A4TSHRALDH1A1MAPK1SLC6A2 | |
| SCHEMBL11297575 | 0.87 | QDPR (0.51) | CYP3A4TSHRALDH1A1MAPK1SLC6A2 | |
| SCHEMBL3792026 | 0.83 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL14167565 | 0.80 | CYP2D6 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL3542983 | 0.80 | IKBKE (0.41) | CYP3A4TSHRALDH1A1MAPK1SLC6A2 | |
| SCHEMBL9870878 | 0.79 | SLC6A2 (0.58) | CYP3A4SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL843886 | 0.79 | HDAC1 (0.44) | CYP3A4TSHRALDH1A1KCNH2HDAC3 | |
| SCHEMBL14167556 | 0.79 | CYP2D6 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-117561255-A | 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors | 辉瑞公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4313981-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | Pfizer Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240002384-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230120188-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| EP-1101756-B1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-6300366-B1 | FOR THERAPY OF CARDIOVASCULAR DISEASES, ESPECIALLY ARTERIAL HYPERTENSION, ARRHYTHMIA | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-1101756-A1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
| EP-0034623-B1 | 2-(2-CHLORO-4-CYCLOPROPYL-PHENYL-IMINO)-IMIDAZOLIDINE, ACID ADDITION SALTS THEREOF, MEDICAMENTS BASED ON SUCH COMPOUNDS AND PREPARATION PROCESS THEREOF | C.H. BOEHRINGER SOHN (DE) | 1983-07-20 | — | — | EP | disclosed |
| EP-0024673-B1 | 2-(2-CHLORO-4-CYCLOPROPYL-PHENYL-IMINO)-IMIDAZOLIDINE, ITS ACID ADDITION SALTS, MEDICAMENTS CONTAINING THE SAME AND PROCESS FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1983-07-20 | — | — | EP | disclosed |
| US-4341788-A | CARDIOTONIC AGENTS; RETARDERS; ANTIARRHYTHMIA AGENTS | C. H. BOEHRINGER SOHN (DE) | 1982-07-27 | — | — | US | disclosed |
| EP-0034623-A1 | 2-(2-CHLORO-4-CYCLOPROPYL-PHENYL-IMINO)-IMIDAZOLIDINE, ACID ADDITION SALTS THEREOF, MEDICAMENTS BASED ON SUCH COMPOUNDS AND PREPARATION PROCESS THEREOF. | BOEHRINGER SOHN INGELHEIM (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0024673-A1 | 2-(2-Chloro-4-cyclopropyl-phenyl-imino)-imidazolidine, its acid addition salts, medicaments containing the same and process for their preparation | C.H. BOEHRINGER SOHN (DE) | 1981-03-11 | — | — | EP | disclosed |
| WO-1981000565-A1 | 2-(2-CHLORO-4-CYCLOPROPYL-PHENYL-IMINO)-IMIDAZOLIDINE,ACID ADDITION SALTS THEREOF,MEDICAMENTS BASED ON SUCH COMPOUNDS AND PREPARATION PROCESS THEREOF | BOEHRINGER SOHN INGELHEIM (DE) | 1981-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | CYP3A4 3769/4885TSHR 3555/4885ALDH1A1 1316/4885 |
| US-20230120188-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, MAPK1 | CYP3A4 1793/4885TSHR 2583/4885ALDH1A1 701/4885 |
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | CYP3A4 1793/4885TSHR 2583/4885ALDH1A1 701/4885 |
| US-20240002384-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | CYP3A4 2722/4885TSHR 3778/4885ALDH1A1 1249/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | CYP3A4 2722/4885TSHR 3778/4885ALDH1A1 1249/4885 |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | CYP3A4 1793/4885TSHR 2583/4885ALDH1A1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.